284.51MMarket Cap-1.33P/E (TTM)
3.110High2.950Low903.14KVolume3.100Open3.110Pre Close2.72MTurnover1.26%Turnover RatioLossP/E (Static)92.67MShares10.31052wk High1.84P/B219.66MFloat Cap2.88052wk Low--Dividend TTM71.55MShs Float61.690Historical High--Div YieldTTM5.15%Amplitude2.880Historical Low3.013Avg Price1Lot Size
COMPASS Pathways Stock Forum
Breakthrough: Single Dose Psilocybin Fights Depression for 189 Days, New Study Shows
Can Compass Pathways' $140M Cash Infusion Offset Growing Losses in Psychedelic Treatment Race?
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
• $Genco Shipping & Trading (GNK.US)$ +4.7% (positive Barrons article)
• $NextDecade (NEXT.US)$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways (CMPS.US)$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo (GOEV.US)$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg (AXL.US)$ +3.7% (pr...
No comment yet